IDEAYA Biosciences, Inc.
IDYA
$40.17
$0.220.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3,244.67% | 3,118.14% | 3,024.43% | 5,377.66% | -41.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,244.67% | 3,118.14% | 3,024.43% | 5,377.66% | -41.47% |
| Cost of Revenue | -0.21% | -15.59% | -15.97% | 55.85% | 62.15% |
| Gross Profit | 84.85% | 85.06% | 89.95% | 54.39% | -70.01% |
| SG&A Expenses | 58.00% | 55.17% | 61.11% | 56.50% | 45.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.30% | 11.27% | 13.19% | 85.29% | 92.39% |
| Operating Income | 43.54% | 49.09% | 51.28% | 7.06% | -100.76% |
| Income Before Tax | 47.25% | 54.39% | 58.58% | 9.76% | -115.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.25% | 54.39% | 58.58% | 9.76% | -115.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.25% | 54.39% | 58.58% | 9.76% | -115.82% |
| EBIT | 43.54% | 49.09% | 51.28% | 7.06% | -100.76% |
| EBITDA | 43.89% | 49.53% | 51.75% | 7.19% | -102.12% |
| EPS Basic | 49.14% | 55.96% | 61.00% | 20.97% | -73.55% |
| Normalized Basic EPS | 49.71% | 56.08% | 60.75% | 15.94% | -71.80% |
| EPS Diluted | 48.59% | 55.37% | 60.37% | 20.24% | -73.55% |
| Normalized Diluted EPS | 49.27% | 55.62% | 60.26% | 15.24% | -71.80% |
| Average Basic Shares Outstanding | 2.14% | 4.25% | 8.37% | 15.83% | 25.88% |
| Average Diluted Shares Outstanding | 2.48% | 4.59% | 8.73% | 16.21% | 25.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |